Synendos AG, a BaseLaunch portfolio company, has been awarded a prestigious grant under the Start-Up Innovation Project (SIP) scheme by Innosuisse. This highly competitive initiative supports Swiss science-based projects with significant socioeconomic impact.
With a total project budget of CHF 2.9 million, this funding will play a crucial role in advancing Synendos’ research. It will help explore the potential of their novel SERI mechanism for treating neuropsychiatric disorders, such as PTSD. The funds will specifically support the study of their Phase 1 candidate, SYT-510, in clinical models of anxiety and stress.
We’re proud to see Innosuisse recognize and back Synendos’ groundbreaking approach.
Original news on Synendos website here.
